Clinical trial
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL) in the Treatment of Moderate…
NCT00002147 · Sequus Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00002147 |
|---|---|
| Title | Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. |
| Official title | Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. |
| Lead sponsor | Sequus Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sarcoma, Kaposi, HIV Infections |
| Intervention type | Drug |
| Interventions | Doxorubicin hydrochloride (liposomal) |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: